Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTXNYSE:GSKNYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$109.65+1.3%$102.74$76.53▼$131.49$26.44B1.29942,387 shs613,718 shsGSKGSK$38.26-0.6%$39.00$31.72▼$44.67$78.17B0.54.93 million shs3.00 million shsJNJJohnson & Johnson$155.90+0.2%$153.68$140.68▼$169.99$375.37B0.418.05 million shs3.48 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%+2.74%-1.35%+24.53%+37.30%GSKGSK0.00%-0.74%-6.29%+4.84%-0.47%JNJJohnson & Johnson0.00%+2.27%+1.64%+1.88%+7.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTXBioNTech2.362 of 5 stars4.42.00.00.01.20.80.0GSKGSK2.356 of 5 stars1.14.02.50.02.60.02.5JNJJohnson & Johnson4.8505 of 5 stars2.35.04.23.93.11.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.83Moderate Buy$137.8625.73% UpsideGSKGSK 2.10Hold$37.38-2.31% DownsideJNJJohnson & Johnson 2.55Moderate Buy$170.889.61% UpsideCurrent Analyst Ratings BreakdownLatest JNJ, BNTX, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$138.006/16/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$145.00 ➝ $138.006/5/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$134.00 ➝ $145.006/5/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.006/3/2025BNTXBioNTechTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$151.00 ➝ $155.006/3/2025GSKGSKBerenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold6/2/2025BNTXBioNTechLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$112.005/29/2025BNTXBioNTechThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Neutral$110.005/22/2025BNTXBioNTechJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$120.00 ➝ $116.005/22/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$134.00 ➝ $134.005/14/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$145.00 ➝ $134.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.98B8.85N/AN/A$87.61 per share1.25GSKGSK$40.10B1.95$5.59 per share6.84$8.07 per share4.74JNJJohnson & Johnson$88.82B4.22$13.11 per share11.89$29.69 per share5.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$719.92M-$3.40N/AN/AN/A-27.37%-3.94%-3.41%8/4/2025 (Estimated)GSKGSK$3.29B$1.9419.728.231.539.89%48.82%11.15%7/30/2025 (Estimated)JNJJohnson & Johnson$14.07B$8.9917.3414.082.3624.42%33.46%13.30%7/16/2025 (Estimated)Latest JNJ, BNTX, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025GSKGSK$1.12N/AN/AN/A$7.92 billionN/A7/16/2025Q2 2025JNJJohnson & Johnson$2.65N/AN/AN/A$22.85 billionN/A4/30/2025Q1 2025GSKGSK$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billion4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AGSKGSK$1.694.42%N/A87.11%N/AJNJJohnson & Johnson$5.203.34%N/A57.84%64 YearsLatest JNJ, BNTX, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025GSKGSKquarterly$0.42164.1%5/16/20255/16/20257/10/20254/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.0110.1810.02GSKGSK1.210.870.58JNJJohnson & Johnson0.491.261.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%GSKGSK15.74%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%GSKGSK10.00%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech6,772240.39 million194.24 millionOptionableGSKGSK68,6292.05 billion1.84 billionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableJNJ, BNTX, and GSK HeadlinesRecent News About These CompaniesThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarJuly 4 at 9:56 AM | zacks.com2 Bulletproof Dividend Stocks to Buy in JulyJuly 4 at 9:40 AM | 247wallst.comGoldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy TailwindsJuly 4 at 6:48 AM | msn.comPinnacle Financial Partners Inc Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comMiller Howard Investments Inc. NY Acquires 99,040 Shares of Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comKanawha Capital Management LLC Has $24.87 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comMoody Lynn & Lieberson LLC Has $22.09 Million Stock Position in Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comFirst Bank & Trust Buys 3,952 Shares of Johnson & Johnson (NYSE:JNJ)July 4 at 5:04 AM | marketbeat.comHarbour Trust & Investment Management Co Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)July 4 at 5:04 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Keybank National Association OHJuly 4 at 4:54 AM | marketbeat.comYukon Wealth Management Inc. Invests $741,000 in Johnson & Johnson (NYSE:JNJ)July 4 at 4:54 AM | marketbeat.comSumitomo Mitsui DS Asset Management Company Ltd Has $88.90 Million Stake in Johnson & Johnson (NYSE:JNJ)July 4 at 4:45 AM | marketbeat.comClear Creek Financial Management LLC Has $1.57 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)July 4 at 4:44 AM | marketbeat.comWhy Johnson & Johnson (JNJ) Could Beat Earnings Estimates AgainJuly 3 at 1:11 PM | zacks.comJohnson & Johnson (JNJ) Could Be a Great ChoiceJuly 3 at 12:46 PM | zacks.comIs Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?July 3 at 10:00 AM | zacks.comJohnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterationsJuly 3 at 8:41 AM | globenewswire.comSmith Group Asset Management LLC Increases Position in Johnson & Johnson (NYSE:JNJ)July 3 at 5:00 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by BLB&B Advisors LLCJuly 3 at 5:00 AM | marketbeat.comGuardian Investment Management Lowers Holdings in Johnson & Johnson (NYSE:JNJ)July 3 at 5:00 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by RKL Wealth Management LLCJuly 3 at 4:59 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJNJ, BNTX, and GSK Company DescriptionsBioNTech NASDAQ:BNTX$109.64 +1.39 (+1.28%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$109.64 0.00 (0.00%) As of 07/3/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.GSK NYSE:GSK$38.26 -0.25 (-0.65%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$38.28 +0.02 (+0.04%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Johnson & Johnson NYSE:JNJ$155.90 +0.34 (+0.22%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$155.75 -0.15 (-0.10%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
